Responding to TGA GMP Non-Compliance Notifications: What Sponsors Need to Know

For many Australian Sponsors, GMP compliance is primarily managed through oversight of their manufacturing partners. However, when the Therapeutic Goods Administration (TGA) issues a GMP non-compliance notification, Sponsors can quickly find themselves managing an urgent and resource-intensive regulatory response.

One of the most challenging aspects of responding to a GMP non-compliance notification is the volume of information that must be gathered within a short timeframe.

The initial notification from the TGA may contain limited information regarding the GMP non-compliance itself, with Sponsors then expected to take the lead in engaging with manufacturers and other relevant parties to establish the nature of the issue, understand which products and manufacturing activities may be affected, and provide the TGA with sufficient information to support its assessment.

This can become particularly complex when the supply chain involves multiple partners and manufacturers, or where overseas affiliates are involved. Obtaining accurate and complete information quickly is often one of the most significant challenges Sponsors face when responding to a GMP non-compliance notification.

While every GMP non-compliance notification is different, the TGA will typically request information relating to three key areas: stock and supply, manufacturer information, and risk assessment.

Sponsors are often required to determine whether any products supplied to Australia may be affected, assess potential impacts on supply, and gather information from the manufacturer regarding the nature of the GMP non-compliance, investigations undertaken, and any corrective actions being implemented.

A comprehensive local risk assessment is a central component of the response and is used to evaluate the potential impact of the GMP non-compliance on product quality, patient safety, and compliance.

While responding to a GMP non-compliance notification is a regulatory requirement, it is also an opportunity for Sponsors to demonstrate effective oversight of their products and supply chain. The quality of the response can influence the TGA’s confidence in the Sponsor’s assessment and management of the issue. A well-supported and timely response helps address regulatory concerns, facilitates efficient TGA review, and supports informed decisions on any actions that may be required to protect patients and maintain supply.

Many Sponsors underestimate the level of coordination required when responding to a GMP non-compliance notification.

Quality, regulatory, supply chain, manufacturing, medical, and commercial teams may all need to contribute information within relatively short timeframes. In some cases, information must be sourced from multiple organisations before a meaningful assessment can be completed.

The most effective responses to GMP non-compliance notifications begin long before a TGA notification is received.

Sponsors that maintain strong oversight of their manufacturing network, understand their supply chains, and have applicable agreements and established processes for managing significant quality events are generally better positioned to respond quickly and effectively when issues arise.

These notifications are often urgent, involve extensive data gathering, and require coordination across multiple organisations. Sponsors may need to obtain stock and supply information, gather details from manufacturers regarding the GMP non-compliance, and conduct a robust risk assessment to support the TGA’s review. Having established processes and experienced personnel can significantly impact the effectiveness of the response.

Commercial Eyes has extensive experience helping Australian Sponsors manage GMP non-compliance notifications. Our team can support the full response process, including manufacturer engagement, information gathering, impact assessments, risk assessments, and preparation of responses to TGA requests. Contact us to discuss how we can assist your organisation in addressing GMP non-compliance notifications with confidence.

The Author:

	Colleen Turnbull Post-Market Quality Services Line Lead CommercialEyes – a PLG Company